Fig. 1From: Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in ChinaVital measurement of skin and muscle involvement of JDM at baseline and follow-up visit. A CMAS. B CAT-BM (CAT activity score and CAT damage score)Back to article page